News & Updates

Dapagliflozin for individuals with heart failure (HF) demonstrates consistent safety and efficacy across regions worldwide despite geographic differences in patient characteristics, background treatment, and event rates, reports a recent study.

Individuals with depression are at higher risk of developing cardiovascular disease (CVD), which may even result in death, suggests a recent study.

Individuals with worsening kidney function are at greater risk of future atherosclerotic cardiovascular diseases (ASCVD), and such risk is more evident among women, according to a study.

Nearly one in three patients with myocardial infarction (MI) develop heart failure or renal failure, while a few of them experience another MI or, worse, die within 10 years, according to a study in England.